Dorsey, E. R. & Bloem, B. R. The Parkinson pandemic—a call to action. JAMA Neurol. 75, 9–10 (2018).
Morris, H. R., Spillantini, M. G., Sue, C. M. & Williams-Gray, C. H. The pathogenesis of Parkinson’s disease. Lancet 403, 293–304 (2024).
Armstrong, M. J. & Okun, M. S. Diagnosis and treatment of Parkinson disease: a review. JAMA 323, 548–560 (2020).
Poewe, W. et al. Parkinson disease. Nat. Rev. Dis. Primers 3, 17013 (2017).
Heimrich, K. G., Schönenberg, A., Santos-García, D., Mir, P., Coppadis Study Group & Prell, T. The impact of nonmotor symptoms on health-related quality of life in Parkinson’s disease: a network analysis approach. J. Clin. Med. 12, 2573 (2023).
Chung, K. A., Lobb, B. M., Nutt, J. G. & Horak, F. B. Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease. Neurology 75, 1263–1269 (2010).
Henderson, E. J. et al. Rivastigmine for gait stability in patients with Parkinson’s disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 15, 249–258 (2016).
Hauser, R. A. et al. A home diary to assess functional status in patients with Parkinson’s disease with motor fluctuations and dyskinesia. Clin. Neuropharmacol. 23, 75–81 (2000).
Kremer, N. I. et al. STN-DBS electrode placement accuracy and motor improvement in Parkinson’s disease: systematic review and individual patient meta-analysis. J. Neurol. Neurosurg. Psychiatry 94, 236–244 (2023).
Krishna, V. et al. Trial of globus pallidus focused ultrasound ablation in Parkinson’s disease. N. Engl. J. Med. 388, 683–693 (2023).
Bond, A. E. et al. Safety and efficacy of focused ultrasound thalamotomy for patients with medication-refractory, tremor-dominant Parkinson disease: a randomized clinical trial. JAMA Neurol. 74, 1412–1418 (2017).
Lang, A. E. et al. Trial of cinpanemab in early Parkinson’s disease. N. Engl. J. Med. 387, 408–420 (2022).
Pagano, G. et al. Trial of prasinezumab in early-stage Parkinson’s disease. N. Engl. J. Med. 387, 421–432 (2022).
Standaert, D. G. GLP-1, Parkinson’s disease, and neuroprotection. N. Engl. J. Med. 390, 1233–1234 (2024).
Meissner, W. G. et al. Trial of lixisenatide in early Parkinson’s disease. N. Engl. J. Med. 390, 1176–1185 (2024).
Abeliovich, A., Hefti, F. & Sevigny, J. Gene therapy for Parkinson’s disease associated with GBA1 mutations. J. Parkinsons Dis. 11, S183–S188 (2021).
Van Laar, A. D. et al. An update on gene therapy approaches for Parkinson’s disease: restoration of dopaminergic function. J. Parkinsons Dis. 11, S173–S182 (2021).
de Bie, R. M. A., Clarke, C. E., Espay, A. J., Fox, S. H. & Lang, A. E. Initiation of pharmacological therapy in Parkinson’s disease: when, why, and how. Lancet Neurol. 19, 452–461 (2020).
Wenning, G. K. et al. Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson’s disease. Ann. Neurol. 42, 95–107 (1997).
Freed, C. R. et al. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson’s disease. N. Engl. J. Med. 327, 1549–1555 (1992).
Brundin, P. et al. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson’s disease. Brain 123, 1380–1390 (2000).
Hagell, P. et al. Sequential bilateral transplantation in Parkinson’s disease: effects of the second graft. Brain 122, 1121–1132 (1999).
Lindvall, O. et al. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson’s disease. Ann. Neurol. 35, 172–180 (1994).
Peschanski, M. et al. Bilateral motor improvement and alteration of l-dopa effect in two patients with Parkinson’s disease following intrastriatal transplantation of foetal ventral mesencephalon. Brain 117, 487–499 (1994).
Olanow, C. W. et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson’s disease. Ann. Neurol. 54, 403–414 (2003).
Freed, C. R. et al. Transplantation of embryonic dopamine neurons for severe Parkinson’s disease. N. Engl. J. Med. 344, 710–719 (2001).
Politis, M. et al. Serotonin neuron loss and nonmotor symptoms continue in Parkinson’s patients treated with dopamine grafts. Sci. Transl. Med. 4, 128ra141 (2012).
Kefalopoulou, Z. et al. Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports. JAMA Neurol 71, 83–87 (2014).
Hallett, P. J. et al. Long-term health of dopaminergic neuron transplants in Parkinson’s disease patients. Cell Rep. 7, 1755–1761 (2014).
Li, W. et al. Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating parkinsonian brain. Proc. Natl Acad. Sci. USA 113, 6544–6549 (2016).
Kriks, S. et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson’s disease. Nature 480, 547–551 (2011).
Steinbeck, J. A. et al. Optogenetics enables functional analysis of human embryonic stem cell-derived grafts in a Parkinson’s disease model. Nat. Biotechnol. 33, 204–209 (2015).
Kim, T. W. et al. Biphasic activation of WNT signaling facilitates the derivation of midbrain dopamine neurons from hESCs for translational use. Cell Stem Cell 28, 343–355 (2021).
Piao, J. et al. Preclinical efficacy and safety of a human embryonic stem cell-derived midbrain dopamine progenitor product, MSK-DA01. Cell Stem Cell 28, 217–229 (2021).
Rudow, G. et al. Morphometry of the human substantia nigra in ageing and Parkinson’s disease. Acta Neuropathol. 115, 461–470 (2008).
Hagell, P. & Brundin, P. Cell survival and clinical outcome following intrastriatal transplantation in Parkinson disease. J. Neuropathol. Exp. Neurol. 60, 741–752 (2001).
Goetz, C. G. et al. Movement Disorder Society-sponsored revision of the unified Parkinson’s disease rating scale (MDS-UPDRS): process, format, and clinimetric testing plan. Mov. Disord. 22, 41–47 (2007).
Nelson, J. et al. Consensus recommendations for use of maintenance immunosuppression in solid organ transplantation: endorsed by the American College of Clinical Pharmacy, American Society of Transplantation, and International Society for Heart and Lung Transplantation: an executive summary. Pharmacotherapy 42, 594–598 (2022).
Neuberger, J. M. et al. Practical recommendations for long-term management of modifiable risks in kidney and liver transplant recipients: a guidance report and clinical checklist by the Consensus on Managing Modifiable Risk in Transplantation (COMMIT) Group. Transplantation 101, S1–S56 (2017).
Martinez–Martin, P., Rodriguez-Blazquez, C. & Forjaz, M. J. in Neuroscience and Biobehavioral Psychology 8–16 (Elsevier, 2017).
Shulman, L. M. et al. The clinically important difference on the unified Parkinson’s disease rating scale. Arch. Neurol. 67, 64–70 (2010).
Ma, Y. et al. Dopamine cell implantation in Parkinson’s disease: long-term clinical and 18F-FDOPA PET outcomes. J. Nucl. Med. 51, 7–15 (2010).
Li, J. Y. et al. Lewy bodies in grafted neurons in subjects with Parkinson’s disease suggest host-to-graft disease propagation. Nat. Med. 14, 501–503 (2008).
Kordower, J. H., Chu, Y., Hauser, R. A., Freeman, T. B. & Olanow, C. W. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson’s disease. Nat. Med. 14, 504–506 (2008).
Barker, R. A. Designing stem-cell-based dopamine cell replacement trials for Parkinson’s disease. Nat. Med. 25, 1045–1053 (2019).
Schweitzer, J. S. et al. Personalized iPSC-derived dopamine progenitor cells for Parkinson’s disease. N. Engl. J. Med. 382, 1926–1932 (2020).
Kirkeby, A. et al. Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the treatment of Parkinson’s disease, STEM-PD. Cell Stem Cell 30, 1299–1314 (2023).
Patenaude, B., Smith, S. M., Kennedy, D. N. & Jenkinson, M. A Bayesian model of shape and appearance for subcortical brain segmentation. Neuroimage 56, 907–922 (2011).
Dhawan, V. et al. Comparative analysis of striatal FDOPA uptake in Parkinson’s disease: ratio method versus graphical approach. J. Nucl. Med. 43, 1324–1330 (2002).
Jokinen, P. et al. Simple ratio analysis of 18F-fluorodopa uptake in striatal subregions separates patients with early Parkinson disease from healthy controls. J. Nucl. Med. 50, 893–899 (2009).
Nakamura, T. et al. Blinded positron emission tomography study of dopamine cell implantation for Parkinson’s disease. Ann. Neurol. 50, 181–187 (2001).
Ma, Y. et al. Dyskinesia after fetal cell transplantation for parkinsonism: a PET study. Ann. Neurol. 52, 628–634 (2002).
